IntelGenx Technologies Corp. Approved for trading on the TSX-Venture Exchange

May 22, 2008

Saint Laurent, Quebec-(CCNMatthews – May 22, 2008) - IntelGenx Technologies Corp. (TSXV:IGX - OTCBB:IGXT)(“IntelGenx” or the “Company”) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has approved the Company's application for the listing of its common shares for trading under the trading symbol “IGX”. The common shares of IntelGenx will commence trading on TSX-V at the opening on May 23, 2008. IntelGenx is already trading and will continue to trade on the OTC-Bulletin Board under the symbol “IGXT”.

Horst Zerbe, President and CEO, said “We are very excited about our listing on the TSX-V. The listing represents a significant milestone in our corporate growth strategy and we expect to enhance shareholder value as a result of the listing.”

IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.  The company’s research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation.


Dr. Horst G.Zerbe, President and CEO


IntelGenx Technologies Corp.
Horst Zerbe, Ph.D.
President and CEO
T: 514-331-7440 (ext. 201)
F: 514-331-0436

The OTCBB has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.